Clinical Trials Logo

Pulmonary Hypertension clinical trials

View clinical trials related to Pulmonary Hypertension.

Filter by:

NCT ID: NCT02651272 Terminated - Sickle Cell Disease Clinical Trials

Macitentan in Pulmonary Hypertension of Sickle Cell Disease

MENSCH
Start date: July 2015
Phase: Phase 2
Study type: Interventional

This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects. Study participation for each subject will last approximately 24 weeks from screening to end of treatment follow-up.

NCT ID: NCT02633293 Terminated - Clinical trials for Pulmonary Hypertension

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Start date: September 15, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your participation in this study is voluntary and will last until you discontinue from the study or the study ends. The study will continue until each subject reaches the Week 108 visit or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner).

NCT ID: NCT02630316 Completed - Clinical trials for Pulmonary Hypertension

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Start date: February 3, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study included 326 patients at approximately 120 clinical trial centers. The treatment phase of the study lasted approximately 16 weeks. Patients who completed all required assessments were eligible to enter an open-label, extension study (RIN-PH-202).

NCT ID: NCT02603068 Withdrawn - Clinical trials for Pulmonary Hypertension

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Start date: February 2016
Phase: Phase 2
Study type: Interventional

This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.

NCT ID: NCT02595541 Completed - Clinical trials for Pulmonary Hypertension

Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension

Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Pulmonary hypertension (PH) is a consequence of an increase in pulmonary vascular resistance (PVR), pulmonary blood flow, pulmonary venous pressure, or a combination of these elements. Pulmonary arterial hypertension is a frequent complication of congenital heart disease, particularly in patients with systemic-to-pulmonary shunts. Persistent exposure o f the pulmonary vasculature to increased blood flow and pressure may result in vascular remodeling and dysfunction. This leads to increased pulmonary vascular resistance and, ultimately, to reversal of the shunt and development of Eisenmenger's syndrome. It may be more appropriate to define pulmonary hypertension according to the ratio of MPAP to mean systemic arterial pressure (MPAP/MAP) because children may have a low mean systemic blood pressure. MPAP/MAP ratio of < 0.25 is normal, a ratio of 0.33-0.5 indicates moderate pulmonary hypertension, and a ratio of > 0.5 is indicative of severe pulmonary hypertension

NCT ID: NCT02594917 Completed - Clinical trials for Pulmonary Hypertension

Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension

Start date: October 2015
Phase:
Study type: Observational

The investigators are performing this research study to determine whether having low iron-sulfur cluster levels can cause a disease known as pulmonary hypertension (PH). PH is defined as abnormally high blood pressure in the arteries of the lungs. Usually, small specialized structures inside each human cell called mitochondria are in charge of generating energy within lung arteries for normal function. During situations of disease or stress, lung arteries undergo a change in the function of mitochondria, resulting in the development of PH. In studies on mice, investigators have learned that alterations in the production of specific metal complexes called iron-sulfur clusters are responsible for these changes. This makes it more likely that mice will develop PH. In this study, the investigators want to find out if alteration of iron-sulfur cluster formation leads to increased likelihood of developing PH in humans.

NCT ID: NCT02587325 Completed - Clinical trials for Pulmonary Hypertension

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

Start date: April 1, 2017
Phase: Phase 1
Study type: Interventional

mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

NCT ID: NCT02580903 Completed - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

MPNPH
Start date: February 2015
Phase:
Study type: Observational

This is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with Myeloproliferative Neoplasms and their prognosis. All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association. All patients will be followed up for a total of five years to identify prognosis.

NCT ID: NCT02571231 Not yet recruiting - Clinical trials for Pulmonary Hypertension

High Flow Ventilation With Volume Guarantee

Start date: November 2015
Phase: N/A
Study type: Interventional

The trial is a pilot study performed in the NICU's at Oslo University Hospital and Haukeland University Hospital preparing a multi-center randomized, controlled unblinded cross-over study, comparing high frequency ventilation (HFV) with and without volume guarantee (VG).

NCT ID: NCT02570737 Enrolling by invitation - Clinical trials for Pulmonary Hypertension

Latin American Pulmonary Hypertension Registry

RELAHP
Start date: April 2014
Phase: N/A
Study type: Observational [Patient Registry]

The RELAHP registry is a Latin-American multinational, multicenter, prospective observational registry-type cohort study, which pretends to identify clinical characteristics, clinical course, management and outcome of all forms of pulmonary hypertension (PH). All consecutively consented patients newly diagnosed with WHO Group I-V PH according to specific hemodynamic criteria on right heart catheterization at the participating centers will be enrolled. Patients will be followed six-monthly for a minimum of five years from the time of enrollment.